PE2499A1 - Composiciones con recubrimientos que controlan la liberacion - Google Patents

Composiciones con recubrimientos que controlan la liberacion

Info

Publication number
PE2499A1
PE2499A1 PE1997000805A PE00080597A PE2499A1 PE 2499 A1 PE2499 A1 PE 2499A1 PE 1997000805 A PE1997000805 A PE 1997000805A PE 00080597 A PE00080597 A PE 00080597A PE 2499 A1 PE2499 A1 PE 2499A1
Authority
PE
Peru
Prior art keywords
active substance
dihydrogenocitrate
matrix
sodium
subject
Prior art date
Application number
PE1997000805A
Other languages
English (en)
Spanish (es)
Inventor
James Albert Napper
Susan Marie Milosovich
William Muldoon
Laurence Rousseau
Joseph Sauer
Original Assignee
Smithkline Beecham Plc
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc, Smithkline Beecham Corp filed Critical Smithkline Beecham Plc
Publication of PE2499A1 publication Critical patent/PE2499A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
PE1997000805A 1996-09-12 1997-09-10 Composiciones con recubrimientos que controlan la liberacion PE2499A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9619074.9A GB9619074D0 (en) 1996-09-12 1996-09-12 Composition

Publications (1)

Publication Number Publication Date
PE2499A1 true PE2499A1 (es) 1999-03-24

Family

ID=10799833

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1997000805A PE2499A1 (es) 1996-09-12 1997-09-10 Composiciones con recubrimientos que controlan la liberacion

Country Status (22)

Country Link
EP (1) EP0929301A2 (no)
JP (1) JP2001500150A (no)
KR (1) KR20000036039A (no)
CN (2) CN1235544A (no)
AR (1) AR008176A1 (no)
AU (1) AU724086B2 (no)
BR (1) BR9711734A (no)
CA (1) CA2265661A1 (no)
CO (1) CO5031291A1 (no)
CZ (1) CZ83299A3 (no)
GB (1) GB9619074D0 (no)
HU (1) HUP9904401A3 (no)
ID (1) ID19589A (no)
IL (1) IL128781A0 (no)
MA (1) MA24359A1 (no)
NO (1) NO991194L (no)
NZ (1) NZ334268A (no)
PE (1) PE2499A1 (no)
PL (1) PL332074A1 (no)
TR (1) TR199900505T2 (no)
WO (1) WO1998010762A2 (no)
ZA (1) ZA978133B (no)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2775597B1 (fr) * 1998-03-04 2001-04-20 Gattefosse Ets Sa Pellet administrable par voie orale apte a ameliorer la biodisponibilite de la substance active, procede de fabrication
NZ505807A (en) * 1998-03-11 2003-01-31 Smithkline Beecham Corp Controlled release oral dosage form containing [R-(Z)]-alpha-(methoxyimino)-alpha-(1-azabicyclo [2.2.2]oct-3-yl)acetonitrile monohydrochloride; useful for the treatment or prophylaxis of dementia
DE19918325A1 (de) * 1999-04-22 2000-10-26 Euro Celtique Sa Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion
FR2796840B1 (fr) 1999-07-26 2003-06-20 Ethypharm Lab Prod Ethiques Comprimes faiblement doses et procede de preparation
US6733781B2 (en) * 2000-12-06 2004-05-11 Wyeth Fast dissolving tablet
AR040682A1 (es) 2002-07-25 2005-04-13 Pharmacia Corp Forma de dosificacion una vez al dia de pramipexol
JP4808612B2 (ja) * 2003-04-25 2011-11-02 田辺三菱製薬株式会社 アルキレンジオキシベンゼン誘導体を含む経口投与用組成物
PL1628642T3 (pl) * 2003-05-14 2007-01-31 Aptalis Pharma Ltd Kontrolowane uwalnianie lekarstwa z kompozycji odpornej in vivo na mechaniczny stres
US20050142191A1 (en) * 2003-06-23 2005-06-30 Neurochem (International) Limited Pharmaceutical formulations of amyloid inhibiting compounds
JP2005272347A (ja) * 2004-03-24 2005-10-06 Ohara Yakuhin Kogyo Kk 固形製剤の製造方法
EP1789021B2 (en) 2004-08-13 2014-10-08 Boehringer Ingelheim International GmbH Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof
EP1778201B1 (en) * 2004-08-13 2014-07-16 Boehringer Ingelheim International GmbH Extended release pellet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof
EP1970056A1 (en) * 2007-03-15 2008-09-17 Polichem S.A. Time-specific delayed/pulsatile release dosage forms
US9132096B1 (en) 2014-09-12 2015-09-15 Alkermes Pharma Ireland Limited Abuse resistant pharmaceutical compositions

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE269330T1 (de) * 1989-04-13 2004-07-15 Beecham Group Plc Chemische verbindungen
GB9409718D0 (en) * 1994-05-14 1994-07-06 Smithkline Beecham Plc Novel compounds
GB9421472D0 (en) * 1994-10-25 1994-12-07 Smithkline Beecham Plc Novel methods
AR004178A1 (es) * 1995-07-29 1998-11-04 Smithkline Beecham Plc Procedimiento para la formulacion de un farmaco, una composicion farmaceutica obtenible mediante este procedimiento y el uso de la misma.

Also Published As

Publication number Publication date
JP2001500150A (ja) 2001-01-09
PL332074A1 (en) 1999-08-30
AU4128897A (en) 1998-04-02
ID19589A (id) 1998-07-23
CN1235544A (zh) 1999-11-17
TR199900505T2 (no) 1999-06-21
KR20000036039A (ko) 2000-06-26
CO5031291A1 (es) 2001-04-27
EP0929301A2 (en) 1999-07-21
CA2265661A1 (en) 1998-03-19
NO991194D0 (no) 1999-03-11
NZ334268A (en) 2000-10-27
AU724086B2 (en) 2000-09-14
WO1998010762A3 (en) 1998-06-04
CN1446535A (zh) 2003-10-08
BR9711734A (pt) 1999-08-24
NO991194L (no) 1999-03-11
ZA978133B (en) 1999-04-12
AR008176A1 (es) 1999-12-09
HUP9904401A2 (hu) 2000-06-28
IL128781A0 (en) 2000-01-31
WO1998010762A2 (en) 1998-03-19
GB9619074D0 (en) 1996-10-23
CZ83299A3 (cs) 1999-08-11
HUP9904401A3 (en) 2001-03-28
MA24359A1 (fr) 1998-07-01

Similar Documents

Publication Publication Date Title
PE2499A1 (es) Composiciones con recubrimientos que controlan la liberacion
US6106862A (en) Once daily analgesic tablet
EP0248447B1 (en) Sustained release formulations
EP1021171B1 (en) Delayed total release gastrointestinal drug delivery system
Bernkop-Schnurch et al. Multifunctional matrices for oral peptide delivery
US5750145A (en) Stable gelatin coated aspirin tablets
AU674583B2 (en) Stable, ingestable and absorbable NADH and NADPH therapeutic compositions
FI88675C (fi) Elastiska filmoeverdrag och deras anvaendning
IL118240A (en) Oral coated capsule dosage form of omega-3 polyunsaturated acid for release of the acid in the intestine
BRPI0317682B1 (pt) Composição farmacêutica de liberação modificada na forma de uma cápsula
UA72483C2 (en) Moxifloxacin-containing pharmaceutical preparation and method for its manufacture
TW200602085A (en) Controlled-release pharmaceutical composition and method for producing same
HUP9900800A2 (hu) Szerves vegyületeket tartalmazó készítmények
ES2245071T3 (es) Procedimiento para obtener una preparacion de tramadol retardada con un perfil de liberacion estable en almacenamiento sin necesidad de tratar termicamente el producto revestido.
CA2229283A1 (en) Prednisolone metasulphobenzoate preparation for the treatment of inflammatory bowel disease
IE58621B1 (en) Pancreatic enzyme products and a process for the preparation thereof
CA2219777A1 (en) Nanoparticles for oral administration of pharmaceutical agents of low solubility
CA2055905A1 (en) Pharmaceutical composition comprising calcium polycarbophil
BR0212155A (pt) Composição farmacêutica
US5958873A (en) Oral formulation for treatment of bacteria-induced diseases of the colon
HUP0001084A2 (hu) 5-ASA-t tartalmazó, módosított hatóanyag-felszabadulást biztosító orális gyógyászati készítmény bélbetegségek kezelésére
ATE342049T1 (de) Mikroverkapselte und mit gesteurter freigabe kräuter formulierungen
ES2234301T3 (es) Acetaminofeno de liberacion prolongada.
BR9912533A (pt) Composição farmacêutica tendo sabor melhorado
RU2496489C2 (ru) Способы и композиции для лечения фенилкетонурии

Legal Events

Date Code Title Description
FD Application declared void or lapsed